• Chest · Mar 2014

    Are Pseudomonas aeruginosa Risk Factors Associated With Pseudomonas Acute Exacerbation of COPD?

    • Marcos Restrepo, Pilar Sanjuan, Santiago Rodriguez-Segade, Natalia Uribe-Giraldo, Marina Blanco-Aparicio, Isabel Otero, Jorge Ricoy, and Hector Verea.
    • Chest. 2014 Mar 1;145(3 Suppl):356A.

    Session TitleCOPD Epidemiology & Physiology PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: European respiratory society (ERS) guidelines recommend to stratify patients with acute exacerbations of COPD (AECOPD) according to the presence or not of risk factors(RF) for Pseudomonas aeruginosa (PA). There is controversy regarding the need to empirically cover PA in clinical practice. Therefore a better understanding of the prevalence and RF for PA in hospitalized patients with AECOPD is critical in order to appropriately adhere to clinical practice guidelines. Aim: 1) Determine the prevalence of PA pathogens and PA risk RF in hospitalized patients with AECOPD; and 2) Assess the association of PA isolation and PA RF among hospitalized patients with AECOPD.MethodsRetrospective cohort study at a tertiary hospital at la Coruna, Spain in 2009. Inclussion:1) Age >40 years old, 2) former or active smokers (>10 ppk/years), 3) prior spirometry (FEV1/FVC<70), and 4) an admission diagnosis of AECOPD. Exclussion: radiological confirmation of pneumonia as the cause of the AECOPD. We assessed the following risk factors: 1) recent hospitalization, 2) frequent or recent administration of antibiotics, 3) FEV <30%, and 4) oral steroid use (>10 mg of prednisolone daily in the last 2 weeks). We performed descriptive statistics and assessed for associations with a p value <0.05 for statistical significant valuesResultsWe identify a PA prevalence rate of 4.2% (n=6) among 143 subjects hospitalized with an AECOPD. The most common PA RF was "frequent or recent administration of antibiotics" (n=33[23%]), followed by severe COPD disease (n=17[12%]), oral steroid use (n=10[7%]), and recent hospitalization (n=3[2%]). PA AECOPD was not associated with frequent or recent administration of antibiotics (Odds ratio [OR] 3.6; 95% confidence interval [CI] 0.7-18.5, p=.13), severe COPD disease (OR 1.5; 95%CI .2-13.8, p=.7), oral steroid use (OR 2.8; 95%CI .3-27.0, p=.4) and recent hospitalization (OR 0, p>.05).ConclusionsThere is a low prevalence of PA among patients with AECOPD. Despite the common presence of PA risk factors, there is no association between risk factors and PA-AECOPD.Clinical ImplicationsDespite the presence of PA risk factors is significative, a small percentage of them are infected with PA. So, at this moment it is difficult to rely only on this factors when deciding PA antibiotic coverage.DisclosureThe following authors have nothing to disclose: Pedro Marcos, Pilar Sanjuan, Santiago Rodriguez-Segade, Natalia Uribe-Giraldo, Marina Blanco-Aparicio, Isabel Otero, Jorge Ricoy, Hector Verea, Marcos RestrepoNo Product/Research Disclosure Information.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.